

Special Issue

Nanotheranostics and Cancer: Where Are We Now?

Message from the Guest Editors

Nanotheranostics promise to provide innovative and more effective approaches for early diagnosis, imaging and therapy. Indeed, the design of nanoparticles to serve therapeutic and diagnostic purposes has dramatically increased, especially for the treatment of cancer. Note that an effective treatment requires improved diagnostic and therapeutic techniques with minimal side-effects. This dual approach enables to understand the location of tumor tissue, the biodistribution of nanoparticles, the progress and efficacy of the treatment, being highly useful for personalized medicine-based therapeutic interventions. In order to expand the theranostic approaches, different active strategies could be used to modulate the surface of nanotheranostic particles, including surface markers, proteins, drugs or genes, also taking advantage of the microenvironment characteristics using stimuli responsive triggers. The development of new nanotheranostic approaches represents an important step forward in the field of drug delivery systems. This Special Issue has the aim of highlighting current progress in the use of the nanotheranostics in cancer treatment.

Guest Editors

Prof. Dr. Alberto Pais

Dr. Carla Vitorino

Dr. João Sousa

Deadline for manuscript submissions

closed (15 November 2018)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



mdpi.com/si/15743

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).